作者: Jiayun Shen , Henry Lik-Yuen Chan , Grace Lai-Hung Wong , Paul Cheung-Lung Choi , Anthony Wing-Hung Chan
DOI: 10.1016/J.JHEP.2011.12.025
关键词: Nonalcoholic fatty liver disease 、 Liver biopsy 、 Biology 、 Fatty acid-binding protein 、 Gastroenterology 、 Endocrinology 、 Fatty liver 、 Steatohepatitis 、 FGF21 、 Internal medicine 、 Body mass index 、 Biomarker (medicine)
摘要: Background & Aims The diagnosis of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is limited by the need for biopsy. We aimed at testing accuracy cytokeratin-18 fragment (CK-18), adipocyte acid binding protein (AFABP) fibroblast growth factor 21 (FGF21) NAFLD NASH. Methods 146 patients with biopsy-proven 74 age- gender-matched healthy controls were included. Serum CK-18, AFABP FGF21 levels determined enzyme-linked immunosorbent assay. Results AFABP, increased in a stepwise fashion control subjects (median 103U/L, 15.4ng/ml, 104pg/ml), non-NASH (263U/L, 18.9ng/ml, 249pg/ml) NASH (418U/L, 19.4ng/ml, 354pg/ml) ( p Conclusions CK-18 most accurate biomarker A two-step approach using further improves diagnosing